Zydus Lifesciences on Thursday announced that its subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Netherlands-based Synthon BV to introduce a generic version of Ozanimod capsules (ZEPOSIA) in the US market.
Synthon has filed an abbreviated new drug application (ANDA) in the United States for Ozanimod, indicated for relapsing forms of multiple sclerosis. The company will handle regulatory approval, manufacturing, and supply, while Zydus will lead commercialization in the US.
“This collaboration with Synthon enables us to bring this important treatment to the US market,” said Punit Patel, President and CEO, Zydus Pharmaceuticals Inc.
The US market opportunity for Ozanimod capsules is estimated at $637 million, according to IQVIA MAT July 2025 data.